stoxline Quote Chart Rank Option Currency Glossary
Rafael Holdings, Inc. (RFL)
1.79  -0.01 (-0.56%)    12-08 16:00
Open: 1.8
High: 1.8
Volume: 2,487
Pre. Close: 1.8
Low: 1.77
Market Cap: 44(M)
Technical analysis
2023-12-08 4:45:44 PM
Short term     
Mid term     
Targets 6-month :  2.2 1-year :  2.57
Resists First :  1.88 Second :  2.2
Pivot price 1.79
Supports First :  1.76 Second :  1.69
MAs MA(5) :  1.79 MA(20) :  1.79
MA(100) :  1.97 MA(250) :  1.98
MACD MACD :  0 Signal :  -0.1
%K %D K(14,3) :  35.5 D(3) :  42.1
RSI RSI(14): 49.6
52-week High :  2.51 Low :  1.44
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ RFL ] has closed above bottom band by 42.8%. Bollinger Bands are 70.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 14 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.8 - 1.81 1.81 - 1.82
Low: 1.75 - 1.76 1.76 - 1.77
Close: 1.77 - 1.79 1.79 - 1.81
Company Description

Rafael Holdings, Inc. holds interests in clinical and early stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. The company operates in two segments, Pharmaceuticals and Real Estate. It engages in the leasing of a commercial office building, as well as an associated 800-car public garage; and development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. The company's lead drug candidate is CPI-613 (devimistat), which is being evaluated in various clinical studies, including two Phase III registrational clinical trials for the treatment of metastatic pancreatic cancer and r/r acute myeloid leukemia. Rafael Holdings, Inc. is headquartered in Newark, New Jersey.

Headline News

Mon, 30 Oct 2023
Rafael Holdings Inc (RFL) Reports Q4 and Full Year Fiscal 2023 Financial Results - Yahoo Finance

Thu, 28 Oct 2021
Here's Why Rafael Holdings Is Plummeting Today - The Motley Fool

Fri, 24 Sep 2021
Rafael Holdings Continues to Expand its Management Team with a Highly Experienced Global Biopharmaceutical ... - PR Newswire

Tue, 14 Sep 2021
Rafael Holdings Appoints Patrick Fabbio as Chief Financial Officer - PR Newswire

Fri, 20 Aug 2021
Rafael Holdings Announces $104.2 Million Private Placement - PR Newswire

Mon, 21 Jun 2021
Rafael Holdings Announces Strategic Merger with Rafael Pharmaceuticals to Form a Focused Late-Stage Clinical ... - PR Newswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Real Estate
Real Estate Services
Shares Out 0 (M)
Shares Float 24 (M)
Held by Insiders 1.591e+007 (%)
Held by Institutions 20.5 (%)
Shares Short 51 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -1.496e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -3 %
Return on Assets (ttm) 839.7 %
Return on Equity (ttm) -8.7 %
Qtrly Rev. Growth 279000 %
Gross Profit (p.s.) -0.84
Sales Per Share -5.38
EBITDA (p.s.) 245509
Qtrly Earnings Growth -0.4 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -11 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.34
Price to Cash Flow 0.72
Stock Dividends
Dividend 0
Forward Dividend 43610
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android